Posts by Mourabit Halima

From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong…

Professor Jun Zhou from Shanghai GoBroad Cancer Hospital and China Pharmaceutical University discusses the pivotal findings of the CheckMate 649 study. This landmark trial has redefined the first-line treatment for advanced gastric cancer, showcasing the power of immunotherapy combined with chemotherapy.

With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer Center. The results were published in Nature Medicine, one of the most respected medical journals worldwide, marking a new step in global recognition for domestically developed therapies.

In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…

In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…

On April 10, 2025, a research team led by Professor Li Zhang and Professor Wenfeng Fang from Sun Yat-sen University Cancer Center published a significant study in the world-renowned journal…

Join us for an exclusive conversation between Prof. Yansong Lin of Peking Union Medical College Hospital and Prof. Lori Wirth at Massachusetts General Hospital. In this special academic exchange, the…